top of page
  • Recruiting
    • Dec 7, 2019

NCT04184050: Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM

Updated: May 26, 2022

NCT04184050: Phase 1/2: Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM


HPN217

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM


Sponsor

Harpoon Therapeutics


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT04184050


Official Title: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma


First Posted : December 3, 2019


Click here to see details on ClinicalTrials.gov

 

Drug: HPN217

BCMA/CD3e Tri-specific T-cell Activating Construct HPN217

BCMA/CD3e Tri-specific T-cell Activating Construct HPN217 (Code C171631)

Anti-BCMA/CD3e TriTAC HPN217

BCMA/CD3 Tri-specific T-cell Activating Construct HPN217

BCMA/CD3e Tri-specific T-cell Activating Construct HPN217

BCMA/CD3e TriTAC HPN217